DataMeds AI (MEDS) has settled litigation tied to a May 11, 2023 purchase agreement, extinguishing about $19 million of balance-sheet liabilities.
Under the Settlement Agreement related to the Wellgistics, LLC Membership Purchase Interest Agreement, the company retired approximately 364,099 shares of its common stock and paid $450,000 in cash. The company said resolving this outstanding litigation will allow greater focus on its Health IT, pharmacy and telemedicine operations, which incorporate its EinsteinRx™ AI platform and PharmacyChain™ smart contracts technology. Additional details are available in a Form 8-K filed with the Securities and Exchange Commission.
DataMEDS AI (MEDS) has completed the acquisition of the Helomics artificial intelligence cancer diagnostics laboratory and related precision oncology CRO central lab services business from Axe Compute (AGPU) for a total purchase value of $1.5 million, paid in DataMEDS common shares and an acquisition note.
DataMEDS acquired Helomics, a CLIA/CAP-certified clinical laboratory in Pittsburgh, including all laboratory equipment, the Predictive Oncology CRO central lab services business and $1.5 million in cash/b. The acquired Helomics business is disclosed as having no third-party debt requiring repayment and no outstanding, unpaid accounts payable beyond ongoing monthly operating expenses. DataMEDS plans to expand Helomics’ activities from tumor molecular profiling and chemosensitivity testing into cancer screening, broader molecular profiling, traditional CLIA lab services and nutritional support for cancer patients, while Axe Compute concentrates on scaling its core AI infrastructure platform.
Axe Compute (AGPU) has sold its legacy AI cancer diagnostics laboratory subsidiary Helomics Corporation to DataMEDS AI (MEDS) in an all‑stock transaction. Axe Compute received common shares and common share equivalents of DataMEDS in exchange for all of Helomics, giving it potential future returns tied to DataMEDS common stock.
This deal completes Axe Compute’s transition into a focused, pure‑play neocloud GPU‑as‑a‑Service business and moves its remaining legacy healthcare asset into DataMEDS’ health data and AI platform. Helomics, based in Pittsburgh, is a functional precision medicine oncology platform that applies artificial intelligence to real‑world tumor data to support drug discovery and cancer treatment decisions.
DataMeds AI (MEDS) and Tollo Health have entered a partnership with NFL Alumni Health to roll out the national Health Lives Here campaign and consumer mobile app. The initiative, backed by Corexa Health’s network of over 6,500 independent pharmacies, aims to expand telehealth and discounted pharmacy-based services for underserved and rural communities.
The Health Lives Here app is designed to consolidate electronic health records, integrate wearables data, and provide a streamlined health dashboard plus access to unique products. The campaign was introduced to pro football alumni during the 2026 Hall of Fame Game weekend in Canton, Ohio, with a media rollout to the general population expected to begin in North Carolina in September 2026 and further details planned for mid-September 2026.
DataMeds AI (NASDAQ:MEDS) announced the U.S. direct-to-consumer launch of medical food Galectovid(TM) for the 2026 Cold & Flu Season, tied to its #Back2School50% campaign offering 50% off online at Tollo Health’s store and DataMeds’ Corexa Pharmacy store.
Galectovid is an over-the-counter medical food for the dietary management of galectin‑1 and galectin‑3 associated viral infections, categorized under section 5(b)(3) of the Orphan Drug Act, with ingredients on the FDA’s GRAS list and intended for use under physician supervision. According to DataMeds AI, effects are expected to begin within hours and the product may be used alongside other natural antiviral products as part of broader acute or chronic viral infection management.
DataMeds AI (NASDAQ:MEDS)/b) reported Q2 2026 net revenues of , up about 14% sequentially versus Q1 2026 but sharply lower than $7.79 million a year earlier. Q2 net loss widened to $18.36 million (‑$7.13 per share) from $6.67 million (‑$5.40 per share) in Q2 2025, driven in part by $8.88 million loss on extinguishment of debt and higher interest and operating expenses.
The company raised $6.5 million in June 2026, restructured $14.5 million of debt and ended June with $2.46 million in cash but a stockholders’ deficit of $19.50 million. Corporate actions included a 1‑for‑50 reverse split, a July 2026 rebrand from Wellgistics Health to DataMeds AI with ticker change to MEDS, and lock‑up agreements covering about 49% of outstanding shares.
Strategically, DataMeds AI agreed to the pending “Datavault Transaction” with Datavault AI (NASDAQ:DVLT), EOS Technology Holdings and Scilex Holdings to expand its PharmacyChain license, acquire QOLPOM biometric patents and a controlling interest in Tollo Health. It plans to launch the Health Lives Here app with NFL Alumni Health in September 2026 targeting GLP‑1 patients in rural communities, supported by Corexa Health and new products such as Forzet, Tollovid and Galectovid.
DataMEDS AI (NASDAQ: MEDS) set September 9, 2026 as the Payment Date for its previously announced distribution of Dream Bowl Meme Coin I tokens to holders of common stock and other eligible equity as of the August 7, 2026 Record Date.
Record holders are entitled to 50 Dream Bowl Tokens per share of common stock (including shares issuable on conversion or exercise of eligible securities). The Board may change the Payment Date or revoke the distribution based on factors including solvency analysis. DataMEDS intends to list the tokens on the Biconomy exchange in Q3 2026. Holders are expected to open a Datavault wallet and sign an Opt-In Agreement. The tokens are described as digital collectibles for personal, non-commercial use, with no equity, dividend, or profit rights and no assurance of any value.
DataMeds AI (NASDAQ:MEDS) reported multiple developments at its Corexa Health pharmacy division, positioning Corexa Pharmacy as a key growth driver for the second half of 2026. July 2026 revenue exceeded $600,000, which the company said stabilizes an annualized run rate above $7 million.
Corexa Pharmacy registered with TrumpRx to offer patients oral and injectable GLP-1 agonist drugs, including Eli Lilly's Foundayo and Novo Nordisk's oral Wegovy, with certain oral options available for as little as $149 out-of-pocket. Companion medical foods Forzet and Galectovid, and dietary supplement Tollovid, manufactured by Tollo Health, are now available alongside other nutraceuticals.
The company launched online store CorexaRx.com/Store and integrated it into the Health Lives Here app, initially introduced for former NFL players via NFL Alumni Health, enabling telemedicine visits, GLP-1 prescriptions, product refills, and health data monitoring. According to DataMeds AI, a public launch of the Health Lives Here app is expected in September 2026 with a staged state-by-state rollout starting in North Carolina.
DataMeds AI (NASDAQ:MEDS) reported it has completed the renaming of its pharmacy and pharmacy hub subsidiaries to Corexa Pharmacy and Corexa Tech & Hub, under a newly renamed pharmacy-focused division, Corexa Health. The company’s pharmaceutical distribution subsidiary will remain Wellgistics.
According to DataMeds AI, the new Corexa Health structure is intended to separate pharmacy operations from other planned healthcare services divisions in telemedicine and diagnostic laboratories. The company also plans to expand its EinsteinRx AI platform using intellectual property licensed from DataVault AI (NASDAQ:DVLT), alongside proposed acquisitions of Tollo Health and QOLPOM-related intellectual property to support rural-focused, direct-to-consumer healthcare services.
DataMeds AI (NASDAQ: MEDS) reiterated the August 7, 2026 record date for its previously announced Dream Bowl Meme Coin dividend, confirming a 50:1 token-to-common-share ratio. The company specified that the official trading platform for Dream Bowl Meme Coin tokens is Biconomy and that the token is not authorized to trade on Coinbase.
According to DataMeds AI, the company also plans to pursue fail-to-deliver notices aggressively. The release further describes DataMeds AI’s Health IT focus, including its EinsteinRx and PharmacyChain platforms and Corexa Health pharmacy subsidiary.